Shineco, INC 8-K filings

Shineco, Inc. has been delisted from The Nasdaq Stock Market LLC due to non-compliance with the minimum bid price requirement, effective October 7, 2025.

Shineco Inc. faces potential delisting from Nasdaq due to non-compliance with the minimum bid price rule, though a review council has temporarily stayed the suspension while a lawsuit against Nasdaq remains pending.

Shineco, Inc. announced the completion of an unregistered offering, issuing 18 million common shares to non-U.S. investors for gross proceeds of $13.5 million.

Shineco, Inc. has filed an amended 8-K to provide the required financial statements for its recently acquired 51% equity interest in InfiniClone Limited, an iPSC technology company, detailing the acquisition's financial impact and InfiniClone's historical performance.

Shineco, Inc.'s subsidiary, Shineco Life Science Group Hong Kong Co., Limited, has completed the acquisition of a 51% equity interest in InfiniClone Limited for $19.9 million in cash and 3.45 million shares of common stock.

Shineco, Inc. has received a Nasdaq staff determination letter indicating non-compliance with the minimum bid price requirement, leading to an impending trading suspension unless an appeal is successfully lodged.

Shineco, Inc.'s Chief Executive Officer and Chief Financial Officer will jointly initiate a stock purchase program of up to $2 million, signaling strong confidence in the company's undervalued common stock.

Shineco, Inc. has entered into a securities purchase agreement to sell 18 million shares of common stock at $0.75 per share to non-U.S. investors, aiming to raise approximately $13.5 million in gross proceeds.

Shineco Inc. finalizes the acquisition of 75% equity interest in FuWang (HK) International, expanding its presence in the medical equipment and software sector.

Shineco Inc. subsidiary finalizes acquisition of a 75% equity interest in FuWang (HK) International in exchange for cash, shares, and equity interests in Dream Partner Limited.

Shineco, Inc. subsidiary, Shineco Life Science Group Hong Kong Co., Limited, enters into a share purchase agreement to acquire 51% of InfiniClone Limited for cash and stock.

Shineco's subsidiary, Shineco Life Science Group Hong Kong Co., Limited, has entered into a stock purchase agreement to acquire a 75% equity interest in FuWang (HK) International Company Limited for a combination of cash, Shineco common stock, and equity interests in Dream Partner Limited.

Shineco, Inc. has entered into a securities purchase agreement to sell 15 million shares of common stock at $2.18 per share to non-U.S. investors, raising $32.7 million.

Shineco Inc. has announced the resignation of independent director Aamir Ali Quraishi, effective December 17, 2024, and the appointment of Jun Fu as his replacement, effective December 3, 2024.

Shineco Inc. has regained compliance with Nasdaq's minimum bid price requirement after its stock price closed at or above $1.00 for ten consecutive days.

Shineco Inc. has announced a 1-for-24 reverse stock split effective November 12, 2024, to meet Nasdaq's minimum share price requirement.

Shineco Inc. will implement a 1-for-24 reverse stock split of its common stock, effective November 12, 2024, reducing the number of outstanding shares to 1,613,898.

Shineco Inc. shareholders approved a 2025 Equity Incentive Plan and a reverse stock split at the company's annual general meeting on October 21, 2024.

Shineco, Inc. successfully raised $8.2 million through the sale of 14,985,000 common shares at $0.55 per share.

Shineco Inc. has received a notice from Nasdaq for failing to maintain a minimum share price of $1.00, placing its listing at risk.

Shineco, Inc. has entered into a securities purchase agreement to sell 14,985,000 shares of common stock at $0.55 per share, raising approximately $8.2 million.

Shineco, Inc. successfully closed a $2 million underwritten public offering of its common stock, with an option for underwriters to purchase additional shares.

Shineco's subsidiary, Fuzhou Meida, has entered into distribution agreements with six distributors for its water-soluble phospholipid concentrate health food beverage, projecting $38 million in sales over three years.

Shineco Inc. has successfully closed a $7 million share offering, issuing 1.4 million shares at $5.00 each to non-U.S. investors.

Shineco, Inc. has successfully regained compliance with Nasdaq's minimum bid price requirement after its stock price remained above $1.00 for ten consecutive business days.

Shineco, Inc. has entered into a securities purchase agreement to sell 1.4 million shares of common stock at $5.00 per share to non-U.S. investors, raising approximately $7 million.

Shineco Inc.'s CEO, COO, and CFO have voluntarily waived their compensation, opting for a nominal $1 annual salary until the company's market capitalization reaches $1 billion.

Shineco Inc. has received a notice from Nasdaq for not maintaining a minimum bid price of $1.00 per share, and has been given a compliance period to rectify the issue.

Shineco Inc. has successfully regained compliance with Nasdaq's minimum bid price requirement after its stock price remained above $1.00 for 15 consecutive business days.

Shineco, Inc. has enacted a 1-for-10 reverse stock split and increased its authorized common stock to 150 million shares to regain compliance with Nasdaq listing requirements.